Global Exosome Diagnostics and Therapeutics Market - 2021-2028

Global Exosome Diagnostics and Therapeutics Market - 2021-2028

Market Overview

The global exosome diagnostics and therapeutics market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Exosomes are nano-vesicles that constitute proteins, DNA, and RNA. Exosomes are vital in cancer diagnosis because they aid cell-to-cell communication. It aids in the regulation of complicated intracellular and extracellular vesicles and hepatocellular carcinoma pathways, which are increasingly relevant in the treatment of neurological diseases and cancer.

Market Dynamics

Advancements in exosome isolation techniques are expected to drive market growth.

With the fast advances in science and technology, many techniques have been developed to isolate exosomes in appreciable quantity and purity. Each technique exploits a particular trait of exosomes, such as their density, shape, size, and surface proteins to aid their isolation. For instance, Ultracentrifugation-based isolation techniques are considered the gold standard and are among the most commonly used and reported techniques in exosome isolation. It is estimated that ultracentrifugation accounts for 56% of all exosome isolation techniques employed by users in exosome research. Many often perceive this approach as easy to use, requiring very little technical expertise, affordability over time (i.e., one ultracentrifuge machine for long-term use), and moderately time-consuming with little or no sample pretreatments.

Moreover, there are two types of ultracentrifugation - analytical and preparative ultracentrifugation. As for exosome isolation, preparative ultracentrifugation plays an integral part since it is meant to fractionate small bioparticles such as viruses, bacteria, subcellular organelles, and extracellular vesicles. Therefore, ultracentrifugation-based techniques have become a rather popular option among researchers in exosome research.

Restraint:

Lack of awareness, high diagnostic costs and a high incidence of cancer in low-income groups, Exosome-based research products are approved under strict regulations are some of the factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has affected the healthcare systems and has a notable impact on the market. There are presently no FDA-approved antiviral medicines for COVID-19, and therapy options to decrease SARS-CoV-2 infection are urgently needed successfully. The COVID-19 pandemic caused significant interruptions to clinical trial execution in

the U.S., affecting essential stakeholders across the industry. Moreover, the stakeholders experienced financial losses, driven by staff leaves and concerns about workers' safety. So far, a variety of techniques have been investigated, one of which is the new exosome-based therapy. Exosomes have been exploited for therapeutic benefits in patients afflicted with various diseases, including COVID-19. In particular, exosomes derived from mesenchymal stem cells (MSCs) are used as cell-free therapeutic agents. Mesenchymal stem cell-derived exosomes reduce the cytokine storm, reverse the inhibition of host antiviral defenses associated with COVID-19 and enhance mitochondrial function repair lung injuries. Thus, the market will undergo impetus growth during the forecast period.

Segment Analysis

Diagnostic segment is expected to hold the largest market share in exosome diagnostics and therapeutics market.

The diagnostic segment accounted for the largest market share in 2020. Early screening and accurate diagnosis are undoubtedly the primary issues for patients with tumors or precancerous lesions, reducing mortality and increasing the recovery rate. Exosomes play critical roles in various physiological and pathological processes, including cancer, pregnancy disorders, cardiovascular diseases, and immune responses. It is crucial to introduce liquid biopsy to clinical practice to reduce invasive operations and promote more precise medical intervention. Noninvasive liquid biopsy shows significant advantages for individualized and accurate diagnosis and treatment. Tumor-derived exosomes (TDEs) are critically related to tumor progression, metastatic niche formation, and immune evasion, which indicates that TDEs may hold great promise for cancer diagnosis, prognosis and treatment response assessment. For instance, In pancreatic cancer, a high probability of KRAS mutation in circulating exoDNA is found early. Given that the elevated level of GPC1+-circulating exosomes occurred in patients with pancreatic ductal carcinoma (PDAC) and colorectal cancer (CRC)compared to healthy controls, this could serve as an early detection tool for tumors in the digestive system. Therefore, from the above statements, the market is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global exosome diagnostics and therapeutics market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of cancer-related deaths, significant rise with a rising focus on life science research, increased diagnostic procedures for cancer, and innovative and advanced applications of isolation kits in the region are some factors that the market is expected to boost in the forecast period. For instance, according to the American Cancer Society, In 2020, an estimated 1.8 million new cancer cases were diagnosed and 606,520 cancer deaths in the United States. In contrast, in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Moreover, AEGLE Therpeutics has spent decades researching clinical applications of mesenchymal stem cells (MSCs) in severe dermatological disorders, including conducting clinical trials in burns and wounds under multiple INDs. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the exosome diagnostics and therapeutics market are Norgen Biotek Corp, Evomic Science LLC, Cell Guidance Systems LLC, ExoDx, Aegle Therapeutics, Capricor Therapeutics, Creative Medical Technologies Holdings and EXOCEL BIO.

Norgen Biotek Corp:

Overview:

Norgen Biotek was founded in 1998 by Dr. Yousef Haj-Ahmad. The company is located in a 24,000 square foot state-of-the-art facility in Thorold, Ontario, Canada, a few blocks from Brock University. Norgen is an ISO 9001, ISO 13485 and Illumina Propel certified fully-integrated Canadian biotechnology company focusing on developing products for sample collection, sample preparation and sample detection and providing comprehensive research services to the scientific community. The Illumina Propel certification emphasizes proficiency with Illumina Next-Generation Sequencing (NGS) to support genetic and genomic research and provide high-quality services to our customers.

Product Portfolio:

Norgen’s Exosome Purification and RNA Isolation Kits: It enables fast, flexible, robust, and convenient all-in-one systems for intact exosome purification from a wide range of cell-free liquid biopsies in addition to the subsequent RNA isolation from both the purified intact exosomes and the circulating cell-free RNA.

Why Purchase the Report?

Visualize the composition of the global exosome diagnostics and therapeutics market segmentation by product type, application, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in global exosome diagnostics and therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global exosome diagnostics and therapeutics market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global exosome diagnostics and therapeutics market report would provide an access to an approx.45+ market data table, 40+ figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Exosome Diagnostics and Therapeutics Market – By Product type

Instruments

Software

Reagents

Global Exosome Diagnostics and Therapeutics Market – By Application

Diagnostics

Therapeutics

Cancer

Pain

Autoimmune conditions

Neurologic diseases

Cardiovascular diseases

Others

Global Exosome Diagnostics and Therapeutics Market – By End user

Hospitals

Cancer Institutes

Diagnostic Centers

Others

Global Exosome Diagnostics and Therapeutics Market - By Region

North America

South America

Europe

Asia Pacific

Middle East & Africa